Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia | Zendy

Adriano Lazzarin | Zendy; Bonaventura Clotet | Zendy; David A. Cooper | Zendy; Jacques Reynes | Zendy; Keikawus Arastéh | Zendy; Mark Nelson | Zendy; Christine Katlama | Zendy; Hans-Jürgen Stellbrink | Zendy; Jean-François Delfraissy | Zendy; Joep M. A. Lange | Zendy; Les Huson | Zendy; Ralph DeMasi | Zendy; Cynthia Wat | Zendy; John Delehanty | Zendy; Claude Drobnes | Zendy; Miklos Salgo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

Author(s) -

Adriano Lazzarin,

Bonaventura Clotet,

David A. Cooper,

Jacques Reynes,

Keikawus Arastéh,

Mark Nelson,

Christine Katlama,

Hans-Jürgen Stellbrink,

Jean-François Delfraissy,

Joep M. A. Lange,

Les Huson,

Ralph DeMasi,

Cynthia Wat,

John Delehanty,

Claude Drobnes,

Miklos Salgo

Publication year - 2003

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa035211

Subject(s) - enfuvirtide , regimen , medicine , viral load , randomization , drug resistance , gastroenterology , randomized controlled trial , surgery , virology , human immunodeficiency virus (hiv) , immunology , biology , gp41 , antigen , microbiology and biotechnology , epitope

The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy and safety of the optimized background regimen alone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research